louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05597371: An Analysis in the Use of Telecommunication Platform
Official title: An Analysis of Changes in the Use of Telecommunication Platform in National Taiwan University Hospital During the Time of Global COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: the Use of the Platform
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2022-10-28
Enrollment: 1000000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ED visits of the emergency department of the National Taiwan University Hospital

Brief summary: The COVID-19 pandemic becomes a global challenge. Beneficial to being an island country and having appropriate policies, there were only few imported cases in Taiwan. However, many locally acquired cases came out in the mid of this May. The hospital policy about containing infection changed accordingly.

A real-time communication platform for the health care workers was designed and embedded in the hospital information system of the emergency department in 2018. The functions included sending messages to certain staff, pop-up reminders, and tracking messages. This study aims to evaluate the use of the communication platform during the COVID pandemic.

Detailed description: The COVID-19 pandemic becomes a global challenge. Beneficial to being an island country and having appropriate policies, there were only few imported cases in Taiwan. However, many locally acquired cases came out in the mid of this May. The hospital policy about containing infection changed accordingly.

A real-time communication platform for the health care workers was designed and embedded in the hospital information system of the emergency department in 2018. The functions included sending messages to certain staff, pop-up reminders, and tracking messages. This study aims to evaluate the use of the communication platform during the COVID pandemic.

Eligibility criteria: Inclusion Criteria:

healthcare workers with using the communication platform.

Exclusion Criteria:

healthcare workers without using the communication platform.

Primary outcomes:
measure: the number of the use of the communication platform during the COVID pandemic
timeFrame: from 2018 to 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Emergency Medicine, National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Wan-Ching Lien
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00570271: Placebo Effects on Blood Pressure
Official title: Physiological Effects of Placebo Interventions to Increase or Decrease Blood Pressure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Blood Pressure
Keywords: placebo effect
blood pressure
autonomic nervous system
prestige
basic research on physiological placebo effects
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2007-12-10
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: A relevant reduction of blood pressure (BP) in placebo-treated control groups is a phenomenon often observed in pharmacological studies of hypertension. This effect was shown to differ from spontaneous remission tendencies and regression to the mean effect by comparing placebo groups with untreated controls. However, it is not fully understood whether these effects are due to a global reaction of the autonomous nervous system (affecting the overall organ systems of the body) or a specific reaction (affecting the cardiovascular system only). We therefore aim to differentiate specific effects (reduction of blood pressure) from global effects (e.g. changes in electrodermal and gastric activity).

In our study we aim to test the following hypotheses:

1. Placebo administration leads to a significant changes of blood pressure compared with untreated controls.
2. The direction of blood pressure change depends on the type of suggestion (either decrease or increase)
3. This effect is specific for blood pressure; changes in electrodermal and gastric activity do not differ between groups.
4. The placebo response can be enhanced by a prestige intervention (information about the suggested drug action given by doctor or in written form).


Eligibility criteria: Inclusion Criteria:

* Informed consent

Exclusion Criteria:

* Not meeting inclusion criteria
* Untreated hypertension (BP \> 140/90) or hypotension(BP \< 100/60)
* Severe systemic disorders (tumors, tbc, diabetes, asthma etc)
* Diseases with influence on cardiovascular or gastrointestinal system
* Pregnancy and lactation phase
* Body mass index \> 30
* Regular intake of drugs with influence on the autonomic nervous system
* Insufficient compliance
* Simultaneous participation in another trial

Primary outcomes:
measure: Mean arterial pressure
timeFrame: 60 minutes
Secondary outcomes:
measure: Heart rate
timeFrame: 60 minutes
measure: skin conductance level
timeFrame: 60 minutes
measure: gastric activity
timeFrame: 60 minutes
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Department of Psychosomatic Medicine and Psychotherapy, Charité University
Study officials:
affiliation: Charité University Berlin
name: Hans-Christian Deter, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00567671: Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia
Official title: Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia or Progressive Keratoconus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Progressive Keratoconus
Corneal Ectasia
Keywords: keratoconus
ectasia
cross-linking
riboflavin
UVA light
cornea
Lead sponsor: Emory University
Sponsor class: OTHER
First posted: 2007-12-05
Enrollment: 160
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.

Detailed description: Subjects are randomized to a control group or a treatment group, with the control group crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is performed as a single treatment. Subjects are followed for at least 12 months to evaluate the long term effects of corneal collagen cross-linking.

Subjects may be referred from other physicians but must return to Emory Vision for completion of all study visits.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of keratoconus with documented progression over the previous 12 months.
* Diagnosis of corneal ectasia
* Must be able to complete all study visits

Exclusion Criteria:

* Prior corneal surgery in the keratoconus group
* Corneal scarring

Primary outcomes:
measure: Change in keratometry
timeFrame: 3 Months
Secondary outcomes:
measure: Best spectacle-corrected visual acuity
timeFrame: 3 Months
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Woolfson Eye Institute
state: Georgia
Study officials:
affiliation: Emory Vision; Emory University
name: R. Doyle Stulting, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hallahan KM, Rocha K, Roy AS, Randleman JB, Stulting RD, Dupps WJ Jr. Effects of corneal cross-linking on ocular response analyzer waveform-derived variables in keratoconus and postrefractive surgery ectasia. Eye Contact Lens. 2014 Nov;40(6):339-44. doi: 10.1097/ICL.0000000000000090.
Clinical trial NCT00747071: Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies
Official title: Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Clostridium Difficile-Associated Diarrhea
Keywords: Clostridium difficile
diarrhea
colostrum
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2008-09-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This clinical study is designed to evaluate the safety and efficacy of oral administration of the food additive colostrum derived antibodies to Clostridium difficile for prevention of Clostridium difficile associated disease (CDAD).


Eligibility criteria: Inclusion Criteria:

* Age 18 or older
* Written informed consent
* At least 3 unformed or watery stools in each of the 2 previous 24 hour periods.
* Confirmed diagnosis of C. difficile associated diarrhea

Exclusion Criteria:

* Pregnant or breast feeding women
* Known allergy to milk or milk products
* Other etiology of diarrhea
* Active or Chronic conditions: IBD, short bowel syndrome, ischemic colitis Ileus
* Pseudomembranous colitis
* White blood count \> 50,000
* Blood in stools
* Laxatives or motility drugs within 12 hours
* Inability to participate in adequate follow up
* Clinically unstable
* Investigator deems unsuitable
* Immune suppression (disease or treatment)
* GI surgery
* Past intestinal parasites

Primary outcomes:
measure: Recurrence of active Clostridium difficile associated diarrhea in index cases
timeFrame: 60 days
measure: New cases of Clostridium difficile associated diarrhea in close hospital contacts.
timeFrame: 60 days
Secondary outcomes:
measure: Disease severity - duration, maximal intensity (number of stools) in index cases.
timeFrame: 60 days
measure: Eradication of Clostridium difficile from stools
timeFrame: 1 year
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
References:
Clinical trial NCT01780571: CPAP/PSV Preoxygenation in Obese Patients
Official title: Continuous Positive Airway Pressure/Pressure Support Preoxygenation of Morbidly Obese Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Anaesthesia
Keywords: Obesity
general anaesthesia
preoxygenation
atelectasis
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2013-01-31
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether continuouse positive airway pressure (CPAP), during induction of anaesthesia in morbidly obese patients, result in higher levels of oxygen in the blood.


Eligibility criteria: Inclusion Criteria:

* body mass index (BMI) \> 35 kg/m2
* scheduled to undergo elective gastric bypass surgery
* age ≥ 18 years
* ASA Physical Status Classification II-III

Exclusion Criteria:

* significant cardiopulmonary disease
* previous abdominal or thoracic surgery
* inability to comprehend the protocol.

Primary outcomes:
measure: Post intubation PaO2levels
timeFrame: 5 minutes after intubation
Secondary outcomes:
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Department of Anesthesiology and Intensive Care Danderyd Hospital
Study officials:
References:
Clinical trial NCT00464971: Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial
Official title: Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Menopause
Postmenopausal Vaginal Atrophy
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2007-04-24
Enrollment: 102
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial was conducted in the United States of America (USA). This trial aimed to evaluate safety and efficacy of 17-beta Estradiol in the treatment of atrophic vaginitis.


Eligibility criteria: Inclusion Criteria:

* Generally healthy
* Postmenopausal
* Hysterectomized or non-hysterectomized
* Moderate or severe vaginal dryness and soreness
* Successful completion of the study VAG/PD/009/USA

Exclusion Criteria:

* Known, suspected, or past history of breast cancer
* Known, suspected, or past history of hormone-dependent tumor
* Genital bleeding of unknown etiology
* Acute thrombophlebitis or thromboembolic disorders or a past history of these conditions, associated with previous estrogen use
* Subjects who had adverse events during the final visit, or discontinued prematurely, or were noncompliant in VAG/PD/009/USA
* Exposure to any investigational new drug (other than what was dispensed in VAG/PD/009/USA) within the previous 30 days

Primary outcomes:
measure: Relief of vaginal symptoms
timeFrame: over 12 months of treatment
measure: Safety: Long-term effect on the endometrium assessed through evaluation of endometrial biopsies. AEs, clinical laboratory data and serum hormone levels
Secondary outcomes:
measure: Vaginal health, vaginal cytology and urethral cytology
Other outcomes:
Locations:
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008 Jan;111(1):67-76. doi: 10.1097/01.AOG.0000296714.12226.0f.
Clinical trial NCT06238271: Evaluation of the Long-term Efficacy and Safety of Monofocal Plate Haptic Intraocular Lens
Official title: Evaluation of the Long-term Efficacy and Safety of Monofocal Plate Haptic Intraocular Lens to be Implanted Into the Eye in Patients Undergoing Cataract Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lens Implantation, Intraocular
Cataract
Keywords: Cataract
Intraocular lens implantation
Phacoemulsification
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
Collaborators: name: VSY Biotechnology
First posted: 2024-02-02
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Our study aims to determine the efficacy and safety of the monofocal plate haptic intraocular lens to be implanted in patients planning for cataract surgery and to determine the complications that may develop due to the lens.

Detailed description: This study was planned to be performed on 300 eyes with surgical indication due to cataracts in Van Yüzüncü Yıl University Faculty of Medicine Ophthalmology Outpatient Clinic. Uncorrected and best-corrected visual acuity, subjective refraction, slit-light biomicroscopy, optical biometry, anterior segment optical coherence tomography, intraocular pressure, endothelial cell count in the pre-and postoperative (1st, 3rd, and 12th months) controls of the patients. Fundus examination will be performed, and postoperative complications and accompanying ocular pathologies will be recorded. Data before and after surgery effectiveness will be evaluated. Reliability will be interpreted by considering postoperative complications.

Eligibility criteria: Inclusion Criteria:

* Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent;
* Patients of any gender
* Assured follow-up examinations
* Biometry measurement preferably compatible with the Lenstar evaluation;
* IOL implanted into the capsular bag with IOL model Acriva BB UDM 611 (UVE material) in one or both eyes

Exclusion Criteria:

* BCVA not available preoperatively or better than 0.3 logMAR pre-op
* Patients unable to meet the limitations of the protocol or likely to non-cooperation during the trial
* Patients with peroperative complications (Such as capsulorhexis problems that affect centralization, failure of the IOL implanting into the bag, posterior capsular rupture, iris damage, vitreous loss, IOL damage, etc.)

Primary outcomes:
measure: Visual acuity
timeFrame: 12 to 18 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Van Yuzuncu Yil University
Study officials:
References:
Clinical trial NCT03704571: A Predictive Model for Inadequate Bowel Preparation
Official title: A Predictive Model for Inadequate Bowel Preparation: Development and Validation With a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bowel Preparation
Keywords: adenoma
bowel preparation
colonoscopy
predictive model
randomized controlled trial
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2018-10-15
Enrollment: 429
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: We aimed to develop a predictive model of inadequate bowel preparation and to further validate it by a randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-75 years undergoing colonoscopy

Exclusion Criteria:

* known or suspected bowel obstruction, stricture or perforation
* compromised swallowing reflex or mental status
* severe chronic renal failure(creatinine clearance \< 30 ml/min)
* severe congestive heart failure (New York Heart Association class III or IV)
* uncontrolled hypertension (systolic blood pressure \> 170 mm Hg, diastolic blood pressure \> 100 mm Hg)
* dehydration
* disturbance of electrolytes
* pregnancy or lactation
* hemodynamically unstable
* unable to give informed consent

Primary outcomes:
measure: Quality of Bowel Preparation
timeFrame: 10 months
Secondary outcomes:
measure: Adenoma Detection Rate
timeFrame: 10 months
measure: Polyp Detection Rate
timeFrame: 10 months
measure: Adverse Events
timeFrame: 10 months
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu Hospital of Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital of Shandong University
name: Xiuli Zuo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04234971: Cost Effectiveness in Alveolar Bone Grafting in Patients with Cleft Lip and Palate
Official title: Cost Effectiveness in Alveolar Bone Grafting in Patients with Cleft Lip and Palate: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Cleft Lip and Palate
Keywords: alveolar bone graft
Bone Morphogenic Protein
Demineralized Bone Matrix
cleft lip
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2020-01-21
Enrollment: 40
Sex: ALL
Minimum age (years): 6
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this trial is to evaluate if the use of Bone Morphogenic Protein(BMP)/Demineralized Bone Matrix (DBM) versus the use of autologous Iliac Crest Bone Graft (ICBG) will result in an increase in total cost effectiveness for patients undergoing alveolar bone graft (ABG) for Cleft Lip and Palate (CLP) and to see if patients who are treated with DBM/BMP will have reduced post-operative pain scores,reduced operative times,and similar rates of bone healing compared to conventional ICBG.


Eligibility criteria: Inclusion Criteria:

* Patient with CLP(unilateral or bilateral)
* Radiographically evident open bone defect of the alveolus
* Dentition evaluated by orthodontist and cleared for ABG surgery

Exclusion Criteria:

* Patients without CLP
* Previous failed repair of alveolar cleft
* Patients who have previously undergone successful ABG
* Patients without an alveolar defect
* Patients whose parents refuse to consent to randomization
* Patients who have a syndromic CLP

Primary outcomes:
measure: Health system costs per successful bone graft.
timeFrame: One year post graft
Secondary outcomes:
measure: Graft Success
timeFrame: 3 months post graft
measure: Infection
timeFrame: 3 months post graft
measure: Fistula Recurrence
timeFrame: 3 months post graft
measure: Rate of Revision ABG
timeFrame: 3 months post graft
measure: Operative Time
timeFrame: 1 day
measure: Anesthesia Time
timeFrame: 1 day
measure: Post Operative Pain Scores
timeFrame: 1 week post operatively
measure: Pain Medication Usage
timeFrame: 1 week post operatively
measure: Post Op Fever
timeFrame: 3 months
measure: Drainage from Fistula
timeFrame: 3 months
measure: Post Op ER Visits
timeFrame: 3 months.
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Matthew Greives, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03349671: Predictors of Intrauterine Growth Restriction
Official title: Second Trimester Doppler Indices and Placental Vascularity as Predictors of Intrauterine Growth Restriction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pre-Eclampsia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-11-21
Enrollment: 300
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who meet the eligibility criteria of the study will be invited to participate and only those who will give agreement on the informed written consent.

Brief summary: The main objectives of modern antenatal care programs are to identify high risk pregnancies then to predict any possibility of adverse pregnancy outcome as early as possible.

The earliest attempts to achieve this goal were possible with the introduction of ultrasound in obstetrical practice in the 1950s. A breakthrough that enabled obstetricians to directly visualize the fetus, placenta and amniotic fluid. At first 2-dimensional (2D) imaging was employed whereby fetal biometry and placental location were detected. Later on, Doppler measurements \& 3-dimensional (3D) representation became feasible further revolutionizing this area


Eligibility criteria: Inclusion Criteria:

1. Pregnant female.
2. Pregnant ± 22 to 26 weeks gestation
3. Singleton pregnancy.
4. Consenting to participate

Exclusion Criteria:

1. Intrauterine fetal death
2. Diagnosed to have Any congenital anomalies
3. Symmetrical IUGR
4. Established fetal compromise that necessitates delivery

Primary outcomes:
measure: The rate of preeclampsia during pregnancy.
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut Faculty of Medicine
Study officials:
References: